cisapride has been researched along with Long QT Syndrome in 72 studies
Cisapride: A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed)
cisapride : The amide resulting from formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with cis-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-amine. It has been used (as its monohydrate or as its tartrate) for the treatment of gastro-oesophageal reflux disease and for non-ulcer dyspepsia, but its propensity to cause cardiac arrhythmias resulted in its complete withdrawal from many countries, including the U.K., and restrictions on its use elsewhere.
Long QT Syndrome: A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Adverse cardiac events, typically long QT syndrome, have been reported in patients treated with the gastrointestinal prokinetic agent cisapride." | 8.81 | Spontaneous adverse event reports of serious ventricular arrhythmias, QT prolongation, syncope, and sudden death in patients treated with cisapride. ( Barbey, JT; Lazzara, R; Zipes, DP, 2002) |
| "The prokinetic drug cisapride is widely used for treating gastro-oesophageal reflux in infants and children." | 8.80 | [Cisapride treatment for children with gastro-esophageal reflux]. ( Hoekstra, JH; Kneepkens, CM; Vandenplas, Y, 1999) |
| "To evaluate the risk of serious ventricular arrhythmia (SVA) with cisapride use in the United States." | 7.71 | Serious ventricular arrhythmias among users of cisapride and other QT-prolonging agents in the United States. ( Cali, C; Enger, C; Walker, AM, 2002) |
| "The purpose of this study was to test the potential utility of mexiletine for the treatment of drug-induced long QT syndrome in vivo." | 7.70 | Effects of mexiletine on the canine cardiovascular system complicating cisapride overdose: potential utility of mexiletine for the treatment of drug-induced long QT syndrome. ( Hashimoto, K; Satoh, Y; Sugiyama, A; Tamura, K, 2000) |
| "Cisapride is frequently used in the newborn and infant for treatment of gastroesophageal reflux." | 7.69 | [Long QT syndrome under cisapride in neonates and infants]. ( Aujard, Y; Bedu, A; Casasoprana, A; Cézard, JP; Denjoy, I; Faure, C; Lupoglazoff, JM, 1997) |
| "Fluoxetine (Prozac) is a widely prescribed drug in adults and children, and it has an active metabolite, norfluoxetine, with a prolonged elimination time." | 5.33 | Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. ( Anderson, CL; Anson, BD; Delisle, BP; Eckhardt, LL; Gillman, BM; Holzem, KM; January, CT; Klemens, CA; Makielski, JC; Rajamani, S; Valdivia, CR, 2006) |
| " Linkage to cisapride was probable, promoted by high dosage and cisapride metabolism inhibition by ranitidine, but its plasma concentration was not measured." | 5.30 | [Syncope with long QT interval in a 39 day-old infant treated with cisapride]. ( Autret, E; Champel, V; Jonville-Bera, AP; Olivier, C; Valdes, L, 1997) |
| " No significant correlation was found between birth weight or gestational age and the change in QTc values during Cisapride treatment in the appropriate for gestational age group." | 5.11 | Intrauterine growth retardation is a risk factor for cisapride-induced QT prolongation in preterm infants. ( Capretti, MG; Corvaglia, L; Faldella, G; Lanari, M; Rotatori, R; Salvioli, GP, 2004) |
| " Of these, 134 were on cisapride therapy for suspected gastroesophageal reflux and 118 were not on cisapride and served as controls." | 5.09 | Effects of cisapride on corrected QT interval, heart rate, and rhythm in infants undergoing polysomnography. ( Benatar, A; Decraene, T; Feenstra, A; Vandenplas, Y, 2000) |
| "Cisapride is a prokinetic agent that facilitates gastrointestinal motility and is widely used for the treatment of gastroesophageal reflux disease (GERD) in adults and children." | 5.08 | Proarrhythmia associated with cisapride in children. ( Berul, CI; Evangelista, JK; Fulton, DR; Hill, SL; Mobassaleh, M; Pizzi, AM, 1998) |
| "Adverse cardiac events, typically long QT syndrome, have been reported in patients treated with the gastrointestinal prokinetic agent cisapride." | 4.81 | Spontaneous adverse event reports of serious ventricular arrhythmias, QT prolongation, syncope, and sudden death in patients treated with cisapride. ( Barbey, JT; Lazzara, R; Zipes, DP, 2002) |
| "The prokinetic drug cisapride is widely used for treating gastro-oesophageal reflux in infants and children." | 4.80 | [Cisapride treatment for children with gastro-esophageal reflux]. ( Hoekstra, JH; Kneepkens, CM; Vandenplas, Y, 1999) |
| "The cardiac sodium channel (SCN5A) mutation L1825P has been identified in a patient with drug-induced torsade de pointes precipitated by the IKr blocker cisapride." | 3.73 | New mechanism contributing to drug-induced arrhythmia: rescue of a misprocessed LQT3 mutant. ( Liu, K; Roden, DM; Viswanathan, PC; Yang, T, 2005) |
| "To evaluate the risk of serious ventricular arrhythmia (SVA) with cisapride use in the United States." | 3.71 | Serious ventricular arrhythmias among users of cisapride and other QT-prolonging agents in the United States. ( Cali, C; Enger, C; Walker, AM, 2002) |
| "A total of 211 infants were enrolled: 84 (17 born prematurely) undergoing cisapride therapy for at least 4 days for suspected gastroesophageal reflux and 127 controls (10 born prematurely), aged between 1 week and 13." | 3.71 | Cisapride plasma levels and corrected QT interval in infants undergoing routine polysomnography. ( Benatar, A; Decraene, T; Feenstra, A; Vandenplas, Y, 2001) |
| "The purpose of this study was to test the potential utility of mexiletine for the treatment of drug-induced long QT syndrome in vivo." | 3.70 | Effects of mexiletine on the canine cardiovascular system complicating cisapride overdose: potential utility of mexiletine for the treatment of drug-induced long QT syndrome. ( Hashimoto, K; Satoh, Y; Sugiyama, A; Tamura, K, 2000) |
| "A 2-month-old infant with gastroesophageal reflux was treated with cisapride." | 3.69 | Cisapride-induced long QT interval. ( Bryant, RM; Fenrich, AL; Grifka, RG; Lewin, MB, 1996) |
| "Cisapride is frequently used in the newborn and infant for treatment of gastroesophageal reflux." | 3.69 | [Long QT syndrome under cisapride in neonates and infants]. ( Aujard, Y; Bedu, A; Casasoprana, A; Cézard, JP; Denjoy, I; Faure, C; Lupoglazoff, JM, 1997) |
| "To compare the pharmacokinetics of two dosing regimens of cisapride and their effects on QT(c) interval." | 2.71 | A comparison of the pharmacokinetics of two dosing regimens of cisapride and their effects on corrected QT interval in premature infants. ( Benatar, A; Bougatef, A; Bruneel, E; Casteels, A; Cools, F; Theyskens, C; Vandenplas, Y, 2003) |
| " QT prolongation by prokinetic agents can raised from different mechanisms: some involve increased plasma concentrations of cisapride due to increased bioavailability by inhibiting P glycoprotein, and inhibition of metabolism or deficit in the elimination." | 2.46 | Prokinetic agents and QT prolongation: a familiar scene with new actors. ( Di Girolamo, G; Keller, GA, 2010) |
| " There were temporal relationships between the events and the initiation of cisapride treatment, increases in the dosage and the receipt of interacting medications." | 2.44 | Application of the bradford hill criteria to assess the causality of cisapride-induced arrhythmia: a model for assessing causal association in pharmacovigilance. ( Perrio, M; Shakir, SA; Voss, S, 2007) |
| "Cisapride has been used in the neonatal population as a first-line gastrointestinal prokinetic agent for managing feeding intolerance secondary to decreased gastrointestinal motility." | 2.40 | Cisapride: the problem of the heart. ( Paes, B; Premji, SS, 1999) |
| " Our data indicate that healthy and diseased individuals exhibit different susceptibilities to cardiotoxic drugs and that use of disease-specific hiPSC-CMs may predict adverse drug responses more accurately than the standard human ether-a-go-go-related gene test or healthy control hiPSC-CM/hESC-CM screening assays." | 1.39 | Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. ( Bers, DM; Diecke, S; Gong, T; Knowles, JW; Lan, F; Lee, AS; Liang, P; Nguyen, PK; Robbins, RC; Sallam, K; Sanchez-Freire, V; Wang, PJ; Wang, Y; Wu, JC, 2013) |
| "Mitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin receptor." | 1.34 | Preclinical electrophysiology assays of mitemcinal (GM-611), a novel prokinetic agent derived from erythromycin. ( Itoh, M; Itoh, Z; Kato, A; Kimura, K; Mizoguchi, K; Omura, S; Suzuki, M; Tabo, M; Takanashi, H, 2007) |
| "Mitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin receptor." | 1.34 | Hemodynamic and electrophysiological effects of mitemcinal (GM-611), a novel prokinetic agent derived from erythromycin in a halothane-anesthetized canine model. ( Itoh, Z; Kato, A; Kimura, K; Mizoguchi, K; Omura, S; Suzuki, M; Tabo, M; Takanashi, H, 2007) |
| "Trazodone has been associated with prolonged QT-interval and increased risk of polymorphous ventricular tachycardias clinically and has demonstrated in vitro inhibition of hERG (human ether-á-go-go-related gene) channel current." | 1.33 | Effect of trazodone on hERG channel current and QT-interval. ( Appleton, N; Lansdell, K; Tarantino, P, 2005) |
| "Fluoxetine (Prozac) is a widely prescribed drug in adults and children, and it has an active metabolite, norfluoxetine, with a prolonged elimination time." | 1.33 | Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. ( Anderson, CL; Anson, BD; Delisle, BP; Eckhardt, LL; Gillman, BM; Holzem, KM; January, CT; Klemens, CA; Makielski, JC; Rajamani, S; Valdivia, CR, 2006) |
| "Torsade de pointes is a rare but potentially fatal ventricular arrhythmia associated with drug-induced delayed repolarization and prolongation of the QT interval." | 1.31 | The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. ( Cox, BF; Gintant, GA; Limberis, JT; McDermott, JS; Wegner, CD, 2001) |
| "Cisapride, which has recently been withdrawn by the Food and Drug Administration and is no longer an approved therapy, was commonly used for preterm infant care to improve the advance of enteral feedings and to reduce reflux and associated apnea." | 1.31 | Cisapride associated with QTc prolongation in very low birth weight preterm infants. ( Ariagno, R; Dubin, A; Kikkert, M; Mirmiran, M, 2001) |
| " Linkage to cisapride was probable, promoted by high dosage and cisapride metabolism inhibition by ranitidine, but its plasma concentration was not measured." | 1.30 | [Syncope with long QT interval in a 39 day-old infant treated with cisapride]. ( Autret, E; Champel, V; Jonville-Bera, AP; Olivier, C; Valdes, L, 1997) |
| "To report a case of QT prolongation and syncopal episodes resulting from concomitant use of cisapride and agents known to inhibit its metabolism." | 1.30 | Syncopal episodes associated with cisapride and concurrent drugs. ( Gray, VS, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 23 (31.94) | 18.2507 |
| 2000's | 39 (54.17) | 29.6817 |
| 2010's | 9 (12.50) | 24.3611 |
| 2020's | 1 (1.39) | 2.80 |
| Authors | Studies |
|---|---|
| Cavalli, A | 1 |
| Poluzzi, E | 1 |
| De Ponti, F | 1 |
| Recanatini, M | 1 |
| Pearlstein, R | 1 |
| Vaz, R | 1 |
| Rampe, D | 1 |
| Hamatani, T | 1 |
| Noda, N | 1 |
| Takagaki, T | 1 |
| Yodo, Y | 1 |
| Kawai, H | 1 |
| Kakuyama, H | 1 |
| Kaji, Y | 1 |
| Fujio, Y | 1 |
| Liang, P | 1 |
| Lan, F | 1 |
| Lee, AS | 1 |
| Gong, T | 1 |
| Sanchez-Freire, V | 1 |
| Wang, Y | 1 |
| Diecke, S | 1 |
| Sallam, K | 1 |
| Knowles, JW | 1 |
| Wang, PJ | 1 |
| Nguyen, PK | 1 |
| Bers, DM | 1 |
| Robbins, RC | 1 |
| Wu, JC | 1 |
| Durdagi, S | 1 |
| Randall, T | 1 |
| Duff, HJ | 1 |
| Chamberlin, A | 1 |
| Noskov, SY | 1 |
| Romero, L | 1 |
| Trenor, B | 1 |
| Yang, PC | 1 |
| Saiz, J | 1 |
| Clancy, CE | 1 |
| Caraballo, L | 1 |
| Molina, G | 1 |
| Weitz, D | 1 |
| Piskulic, L | 1 |
| Avila, A | 1 |
| Marzi, M | 1 |
| Dubois, VF | 2 |
| Casarotto, E | 1 |
| Danhof, M | 2 |
| Della Pasqua, O | 2 |
| Chen, Z | 1 |
| Xian, W | 1 |
| Bellin, M | 1 |
| Dorn, T | 1 |
| Tian, Q | 1 |
| Goedel, A | 1 |
| Dreizehnter, L | 1 |
| Schneider, CM | 1 |
| Ward-van Oostwaard, D | 1 |
| Ng, JK | 1 |
| Hinkel, R | 1 |
| Pane, LS | 1 |
| Mummery, CL | 1 |
| Lipp, P | 1 |
| Moretti, A | 1 |
| Laugwitz, KL | 1 |
| Sinnecker, D | 1 |
| Dabhi, J | 1 |
| Mehta, A | 1 |
| Collins, KK | 1 |
| Sondheimer, JM | 1 |
| Keller, GA | 1 |
| Di Girolamo, G | 1 |
| Di Veroli, GY | 1 |
| Davies, MR | 1 |
| Zhang, H | 1 |
| Abi-Gerges, N | 1 |
| Boyett, MR | 1 |
| Chain, AS | 1 |
| Sturkenboom, MC | 1 |
| Fossa, AA | 1 |
| DePasquale, MJ | 1 |
| Raunig, DL | 1 |
| Avery, MJ | 1 |
| Leishman, DJ | 1 |
| Marx, M | 1 |
| Kitzmueller, E | 1 |
| Pichler, A | 1 |
| Arbeiter, K | 1 |
| Aufricht, C | 1 |
| Makita, N | 1 |
| Horie, M | 1 |
| Nakamura, T | 1 |
| Ai, T | 1 |
| Sasaki, K | 1 |
| Yokoi, H | 1 |
| Sakurai, M | 1 |
| Sakuma, I | 1 |
| Otani, H | 1 |
| Sawa, H | 1 |
| Kitabatake, A | 1 |
| Chen, J | 1 |
| Seebohm, G | 1 |
| Sanguinetti, MC | 1 |
| Enger, C | 1 |
| Cali, C | 1 |
| Walker, AM | 1 |
| Wu, MH | 1 |
| Su, MJ | 1 |
| Sun, SS | 1 |
| Cools, F | 2 |
| Benatar, A | 5 |
| Bruneel, E | 1 |
| Theyskens, C | 1 |
| Bougatef, A | 2 |
| Casteels, A | 1 |
| Vandenplas, Y | 6 |
| Sugiyama, A | 2 |
| Woroń, J | 1 |
| Trabka-Janik, E | 1 |
| Kostka-Trabka, E | 1 |
| Hamlin, RL | 1 |
| Kijtawornrat, A | 1 |
| Keene, BW | 1 |
| Hamlin, DM | 1 |
| Tamariz-Martel Moreno, A | 1 |
| Baño Rodrigo, A | 1 |
| Sánchez Bayle, M | 1 |
| Montero Luis, C | 1 |
| Acuña Quirós, MD | 1 |
| Cano Fernández, J | 1 |
| Corvaglia, L | 1 |
| Faldella, G | 1 |
| Rotatori, R | 1 |
| Lanari, M | 1 |
| Capretti, MG | 1 |
| Salvioli, GP | 1 |
| Tarantino, P | 1 |
| Appleton, N | 1 |
| Lansdell, K | 1 |
| Shiotani, M | 1 |
| Harada, T | 1 |
| Abe, J | 1 |
| Sawada, Y | 1 |
| Hashimoto, K | 2 |
| Hamada, Y | 1 |
| Horii, I | 1 |
| Liu, K | 1 |
| Yang, T | 1 |
| Viswanathan, PC | 1 |
| Roden, DM | 1 |
| Rajamani, S | 1 |
| Eckhardt, LL | 1 |
| Valdivia, CR | 1 |
| Klemens, CA | 1 |
| Gillman, BM | 1 |
| Anderson, CL | 1 |
| Holzem, KM | 1 |
| Delisle, BP | 1 |
| Anson, BD | 1 |
| Makielski, JC | 1 |
| January, CT | 3 |
| Perrio, M | 1 |
| Voss, S | 1 |
| Shakir, SA | 1 |
| Morissette, P | 1 |
| Hreiche, R | 1 |
| Turgeon, J | 1 |
| Kimura, K | 2 |
| Tabo, M | 2 |
| Itoh, M | 1 |
| Mizoguchi, K | 2 |
| Kato, A | 2 |
| Suzuki, M | 2 |
| Itoh, Z | 2 |
| Omura, S | 2 |
| Takanashi, H | 2 |
| Bran, S | 1 |
| Murray, WA | 1 |
| Hirsch, IB | 1 |
| Palmer, JP | 1 |
| Lewin, MB | 1 |
| Bryant, RM | 1 |
| Fenrich, AL | 1 |
| Grifka, RG | 1 |
| Wysowski, DK | 1 |
| Bacsanyi, J | 1 |
| Bedu, A | 2 |
| Lupoglazoff, JM | 2 |
| Faure, C | 2 |
| Denjoy, I | 2 |
| Casasoprana, A | 2 |
| Aujard, Y | 2 |
| Hanson, R | 1 |
| Browne, G | 1 |
| Fasher, B | 1 |
| Mcaskill, M | 1 |
| Moroney, P | 1 |
| Hawker, R | 1 |
| Gunasekaran, TS | 1 |
| DuBrow, I | 1 |
| Carlsson, L | 1 |
| Amos, GJ | 1 |
| Andersson, B | 1 |
| Drews, L | 1 |
| Duker, G | 1 |
| Wadstedt, G | 1 |
| Cézard, JP | 1 |
| Valdes, L | 1 |
| Champel, V | 1 |
| Olivier, C | 1 |
| Jonville-Bera, AP | 1 |
| Autret, E | 1 |
| el-Shafei, AG | 1 |
| Bjerregaard, P | 1 |
| Mohammad, S | 1 |
| Zhou, Z | 2 |
| Gong, Q | 2 |
| Darpö, B | 1 |
| Hill, SL | 1 |
| Evangelista, JK | 1 |
| Pizzi, AM | 1 |
| Mobassaleh, M | 1 |
| Fulton, DR | 1 |
| Berul, CI | 1 |
| Gray, VS | 1 |
| Khongphatthanayothin, A | 1 |
| Lane, J | 1 |
| Thomas, D | 1 |
| Yen, L | 1 |
| Chang, D | 1 |
| Bubolz, B | 1 |
| Kantoch, MJ | 1 |
| Qurashi, MM | 1 |
| Bulbul, ZR | 1 |
| Gorgels, AP | 1 |
| Trinkle, R | 1 |
| Feenstra, A | 3 |
| Decraene, T | 4 |
| Dubin, AM | 1 |
| Van Hare, GF | 1 |
| Kneepkens, CM | 1 |
| Hoekstra, JH | 1 |
| Heeringa, M | 1 |
| Pulles-Heintzberger, CF | 1 |
| van Puijenbroek, EP | 1 |
| Verduijn, MM | 1 |
| Premji, SS | 1 |
| Paes, B | 1 |
| Napolitano, C | 1 |
| Schwartz, PJ | 1 |
| Brown, AM | 2 |
| Ronchetti, E | 1 |
| Bianchi, L | 1 |
| Pinnavaia, A | 1 |
| Acquaro, G | 1 |
| Priori, SG | 1 |
| Guala, A | 1 |
| Pastore, G | 1 |
| Licardi, G | 1 |
| Noè, G | 1 |
| Zolezzi, F | 1 |
| Tutar, HE | 1 |
| Kansu, A | 1 |
| Kalayci, AG | 1 |
| Girgin, N | 1 |
| Atalay, S | 1 |
| Imamoğlu, A | 1 |
| Satoh, Y | 1 |
| Tamura, K | 1 |
| Ramírez-Mayans, J | 1 |
| Garrido-García, LM | 1 |
| Huerta-Tecanhuey, A | 1 |
| Gutierrez-Castrellón, P | 1 |
| Cervantes-Bustamante, R | 1 |
| Mata-Rivera, N | 1 |
| Zárate-Mondragón, F | 1 |
| Semama, DS | 1 |
| Bernardini, S | 1 |
| Louf, S | 1 |
| Laurent-Atthalin, B | 1 |
| Gouyon, JB | 1 |
| Gintant, GA | 1 |
| Limberis, JT | 1 |
| McDermott, JS | 1 |
| Wegner, CD | 1 |
| Cox, BF | 1 |
| Dubin, A | 1 |
| Kikkert, M | 1 |
| Mirmiran, M | 1 |
| Ariagno, R | 1 |
| Kii, Y | 1 |
| Nakatsuji, K | 1 |
| Nose, I | 1 |
| Yabuuchi, M | 1 |
| Mizuki, Y | 1 |
| Ito, T | 1 |
| Ficker, E | 1 |
| Obejero-Paz, CA | 1 |
| Zhao, S | 1 |
| Finley, MR | 1 |
| Li, Y | 1 |
| Hua, F | 1 |
| Lillich, J | 1 |
| Mitchell, KE | 1 |
| Ganta, S | 1 |
| Gilmour, RF | 1 |
| Freeman, LC | 1 |
| Barbey, JT | 1 |
| Lazzara, R | 1 |
| Zipes, DP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study[NCT02738749] | 450 participants (Anticipated) | Interventional | 2014-06-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 reviews available for cisapride and Long QT Syndrome
| Article | Year |
|---|---|
Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior.
Topics: Cation Transport Proteins; DNA-Binding Proteins; Drug-Related Side Effects and Adverse Reactions; ER | 2003 |
[Proarrhythmic effects of domperidone in infants: a systematic review].
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Cisapride; Contraindications; Cytochrome P-450 CYP3A; Dom | 2014 |
Prokinetic agents and QT prolongation: a familiar scene with new actors.
Topics: Adverse Drug Reaction Reporting Systems; Animals; ATP Binding Cassette Transporter, Subfamily B, Mem | 2010 |
[Effects of clinically available drugs on the repolarization process of the heart assessed by the in vivo canine models].
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Antipsychotic Agents; Antitubercular Agents; Cat | 2003 |
[Side effects, unwanted drug interactions and the problem of cardiotoxicity].
Topics: Cisapride; Drug Interactions; Fluoroquinolones; Histamine H1 Antagonists; Humans; Long QT Syndrome; | 2003 |
Application of the bradford hill criteria to assess the causality of cisapride-induced arrhythmia: a model for assessing causal association in pharmacovigilance.
Topics: Adverse Drug Reaction Reporting Systems; Cisapride; Evidence-Based Medicine; Humans; Long QT Syndrom | 2007 |
[Severe proarrhythmias in cisapride therapy. Simple precautionary measures reduce the risk].
Topics: Anti-Ulcer Agents; Arrhythmias, Cardiac; Cisapride; Humans; Long QT Syndrome; Piperidines; Risk Fact | 1997 |
Advances in the treatment of cardiac rhythm disturbances.
Topics: Adrenergic alpha-Agonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cisapride; Electrophysiolog | 1999 |
[Cisapride treatment for children with gastro-esophageal reflux].
Topics: Child; Cisapride; Drug Approval; Drug Interactions; Gastroesophageal Reflux; Gastrointestinal Agents | 1999 |
Cisapride: the problem of the heart.
Topics: Canada; Cisapride; Contraindications; Drug Information Services; Drug Interactions; Drug Monitoring; | 1999 |
Spontaneous adverse event reports of serious ventricular arrhythmias, QT prolongation, syncope, and sudden death in patients treated with cisapride.
Topics: Arrhythmias, Cardiac; Cisapride; Death, Sudden, Cardiac; Gastrointestinal Agents; Humans; Long QT Sy | 2002 |
9 trials available for cisapride and Long QT Syndrome
| Article | Year |
|---|---|
Thorough QT/QTc Study Shows That a Novel 5-HT
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Arrhythmias, Cardiac; Asian People; Benzamides; | 2020 |
Identifying the translational gap in the evaluation of drug-induced QTc interval prolongation.
Topics: Adolescent; Adult; Animals; Aza Compounds; Bayes Theorem; Cisapride; Cross-Over Studies; Dogs; Doubl | 2013 |
A comparison of the pharmacokinetics of two dosing regimens of cisapride and their effects on corrected QT interval in premature infants.
Topics: Age Factors; Cisapride; Drug Administration Schedule; Electrocardiography; Gastrointestinal Agents; | 2003 |
Intrauterine growth retardation is a risk factor for cisapride-induced QT prolongation in preterm infants.
Topics: Anti-Ulcer Agents; Birth Weight; Cisapride; Electrocardiography; Female; Fetal Growth Retardation; H | 2004 |
Proarrhythmia associated with cisapride in children.
Topics: Adolescent; Child; Child, Preschool; Cisapride; Electrocardiography; Gastroesophageal Reflux; Gastro | 1998 |
Effects of cisapride on QT interval in children.
Topics: Child; Cisapride; Electrocardiography; Female; Gastrointestinal Agents; Humans; Infant; Long QT Synd | 1998 |
Cisapride and proarrhythmia in childhood.
Topics: Cisapride; Electrocardiography; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Infant; In | 1999 |
Cisapride and QTc interval in children.
Topics: Adolescent; Arrhythmias, Cardiac; Child; Child, Preschool; Cisapride; Electrocardiography, Ambulator | 2000 |
Effects of cisapride on corrected QT interval, heart rate, and rhythm in infants undergoing polysomnography.
Topics: Arrhythmias, Cardiac; Cisapride; Electrocardiography; Gastroesophageal Reflux; Gastrointestinal Agen | 2000 |
52 other studies available for cisapride and Long QT Syndrome
| Article | Year |
|---|---|
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go- | 2002 |
Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity.
Topics: Action Potentials; Cardiomyopathy, Dilated; Cardiomyopathy, Hypertrophic, Familial; Cell Differentia | 2013 |
Rehabilitating drug-induced long-QT promoters: in-silico design of hERG-neutral cisapride analogues with retained pharmacological activity.
Topics: Cisapride; Drug Design; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Gastrointestinal A | 2014 |
In silico screening of the impact of hERG channel kinetic abnormalities on channel block and susceptibility to acquired long QT syndrome.
Topics: Action Potentials; Anti-Arrhythmia Agents; Astemizole; Cisapride; Computer Simulation; Gene Expressi | 2014 |
Pharmacokinetic-pharmacodynamic modelling of drug-induced QTc interval prolongation in man: prediction from in vitro human ether-à-go-go-related gene binding and functional inhibition assays and conscious dog studies.
Topics: Animals; Binding Sites; Cells, Cultured; Cisapride; Consciousness; Dogs; Dose-Response Relationship, | 2016 |
Subtype-specific promoter-driven action potential imaging for precise disease modelling and drug testing in hiPSC-derived cardiomyocytes.
Topics: Action Potentials; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Case-Control Studies; Cisapride; Dr | 2017 |
QT prolongation and safety in the Indian population.
Topics: Astemizole; Cisapride; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Electroc | 2007 |
Domperidone-induced QT prolongation: add another drug to the list.
Topics: Animals; Cisapride; Domperidone; Dopamine Antagonists; Drug-Related Side Effects and Adverse Reactio | 2008 |
High-throughput screening of drug-binding dynamics to HERG improves early drug safety assessment.
Topics: Action Potentials; Animals; CHO Cells; Cisapride; Computer Simulation; Cricetinae; Cricetulus; Dogs; | 2013 |
The relationship of clinical QT prolongation to outcome in the conscious dog using a beat-to-beat QT-RR interval assessment.
Topics: Animals; Anti-Arrhythmia Agents; Butylamines; Cisapride; Disease Models, Animal; Dogs; Female; Heart | 2002 |
Effect of cisapride on rate-corrected QT intervals in children on peritoneal dialysis.
Topics: Child; Child, Preschool; Cisapride; Electrocardiography; Female; Gastrointestinal Agents; Humans; In | 2002 |
Drug-induced long-QT syndrome associated with a subclinical SCN5A mutation.
Topics: Aged; Amino Acid Sequence; Base Sequence; Cell Line; Cisapride; Electric Conductivity; Electrocardio | 2002 |
Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels.
Topics: Amino Acid Sequence; Amino Acids, Aromatic; Animals; Binding Sites; Cation Transport Proteins; Cisap | 2002 |
Serious ventricular arrhythmias among users of cisapride and other QT-prolonging agents in the United States.
Topics: Adolescent; Adult; Age Distribution; Age Factors; Arrhythmias, Cardiac; Child; Child, Preschool; Cis | 2002 |
Age-related differences in the direct cardiac effects of cisapride: narrower safety range in the hearts of young rabbits.
Topics: Age Factors; Animals; Animals, Newborn; Atrioventricular Node; Bundle of His; Cisapride; Electrocard | 2003 |
QT and RR intervals in conscious and anesthetized guinea pigs with highly varying RR intervals and given QTc-lengthening test articles.
Topics: Anesthesia; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cisapride; Consciousness; Electro | 2003 |
[Effects of cisapride on QT interval in children].
Topics: Adolescent; Age Distribution; Child; Child, Preschool; Cisapride; Electrocardiography; Female; Gastr | 2004 |
Effect of trazodone on hERG channel current and QT-interval.
Topics: Action Potentials; Animals; Cell Line; Cisapride; Dose-Response Relationship, Drug; ERG1 Potassium C | 2005 |
Practical application of guinea pig telemetry system for QT evaluation.
Topics: Animals; Anti-Arrhythmia Agents; Antipsychotic Agents; Bepridil; Cisapride; Disease Models, Animal; | 2005 |
New mechanism contributing to drug-induced arrhythmia: rescue of a misprocessed LQT3 mutant.
Topics: Action Potentials; Animals; CHO Cells; Cisapride; Cricetinae; Humans; Ion Channel Gating; Long QT Sy | 2005 |
Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.
Topics: Adult; Antidepressive Agents, Second-Generation; Blotting, Western; Cell Line; Cell Membrane; Cisapr | 2006 |
Modulatory role of verapamil treatment on the cardiac electrophysiological effects of cisapride.
Topics: Action Potentials; Animals; Calcium Channel Blockers; Cells, Cultured; Cisapride; Dose-Response Rela | 2006 |
Preclinical electrophysiology assays of mitemcinal (GM-611), a novel prokinetic agent derived from erythromycin.
Topics: Action Potentials; Animals; Cell Line; Cisapride; Dose-Response Relationship, Drug; Drug Evaluation, | 2007 |
Hemodynamic and electrophysiological effects of mitemcinal (GM-611), a novel prokinetic agent derived from erythromycin in a halothane-anesthetized canine model.
Topics: Action Potentials; Anesthesia, General; Anesthetics, Inhalation; Animals; Blood Pressure; Cardiac Pa | 2007 |
Long QT syndrome during high-dose cisapride.
Topics: Cisapride; Electrocardiography; Gastrointestinal Agents; Humans; Long QT Syndrome; Male; Middle Aged | 1995 |
Cisapride-induced long QT interval.
Topics: Adult; Age Factors; Bradycardia; Cisapride; Electrocardiography; Female; Gastroesophageal Reflux; Hu | 1996 |
Cisapride and fatal arrhythmia.
Topics: Anti-Bacterial Agents; Antifungal Agents; Cisapride; Drug Interactions; Drug Labeling; Humans; Imida | 1996 |
Cisapride high dosage and long QT interval.
Topics: Cisapride; Gastroesophageal Reflux; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Prem | 1997 |
Cisapride-induced prolonged QT interval: too much of a good thing!
Topics: Cisapride; Drug Overdose; Female; Gastroesophageal Reflux; Humans; Infant; Long QT Syndrome; Piperid | 1997 |
Cisapride-induced long QT interval: what is the role of ranitidine?
Topics: Anti-Ulcer Agents; Cisapride; Humans; Infant; Long QT Syndrome; Piperidines; Ranitidine | 1997 |
Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential?
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Benzamides; Cisapride; Guinea Pigs; Heart; In Vitr | 1997 |
[Long QT syndrome under cisapride in neonates and infants].
Topics: Anti-Ulcer Agents; Cisapride; Dose-Response Relationship, Drug; Electrocardiography; Female; Gastroe | 1997 |
[Syncope with long QT interval in a 39 day-old infant treated with cisapride].
Topics: Anti-Ulcer Agents; Cisapride; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gastroeso | 1997 |
Long QT interval.
Topics: Cisapride; Gastrointestinal Agents; Humans; Hypokalemia; Long QT Syndrome; Piperidines | 1997 |
Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride.
Topics: Cation Transport Proteins; Cell Line; Cisapride; DNA-Binding Proteins; Dose-Response Relationship, D | 1997 |
Syncopal episodes associated with cisapride and concurrent drugs.
Topics: Accidents, Traffic; Anti-Bacterial Agents; Anti-Ulcer Agents; Cisapride; Clarithromycin; Cytochrome | 1998 |
A newborn with a complex congenital heart disease, atrioventricular block, and torsade de pointes ventricular tachycardia.
Topics: Cisapride; Electrocardiography; Female; Heart Block; Heart Defects, Congenital; Humans; Infant, Newb | 1998 |
Comment: syncopal episodes associated with cisapride.
Topics: Cisapride; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Gastrointestinal Ag | 1999 |
Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome. Pharmacological and temperature effects.
Topics: Anti-Arrhythmia Agents; Astemizole; Biological Transport; Cation Transport Proteins; Cell Compartmen | 1999 |
[Lengthening of the QT-interval in a newborn treated with cisapride].
Topics: Cisapride; Contraindications; Female; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Infa | 1999 |
Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias.
Topics: Aged; Arrhythmias, Cardiac; Cisapride; Critical Illness; Female; Gastrointestinal Agents; Humans; KC | 2000 |
Effects of cisapride on QT interval in infants: A prospective study.
Topics: Cisapride; Gastrointestinal Agents; Humans; Infant; Infant, Newborn; Long QT Syndrome; Prospective S | 2000 |
Effects of cisapride on ventricular repolarization in children.
Topics: Action Potentials; Adolescent; Adult; Arrhythmias, Cardiac; Child; Child, Preschool; Cisapride; Cyto | 2000 |
Effects of mexiletine on the canine cardiovascular system complicating cisapride overdose: potential utility of mexiletine for the treatment of drug-induced long QT syndrome.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Cardiac Output; Cardiovascular System; Cisapride | 2000 |
Effects of cisapride on QTc interval in term neonates.
Topics: Analysis of Variance; Calcium; Cisapride; Double-Blind Method; Electrocardiography; Gastrointestinal | 2001 |
The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.
Topics: Action Potentials; Animals; Anti-Infective Agents; Arrhythmias, Cardiac; Aza Compounds; Cisapride; D | 2001 |
Cisapride associated with QTc prolongation in very low birth weight preterm infants.
Topics: Arrhythmias, Cardiac; Cisapride; Dose-Response Relationship, Drug; Drug and Narcotic Control; Electr | 2001 |
Cisapride plasma levels and corrected QT interval in infants undergoing routine polysomnography.
Topics: Age Factors; Case-Control Studies; Cisapride; Electrocardiography; Female; Gastroesophageal Reflux; | 2001 |
Effects of 5-HT(4) receptor agonists, cisapride and mosapride citrate on electrocardiogram in anaesthetized rats and guinea-pigs and conscious cats.
Topics: Anesthesia; Animals; Benzamides; Cats; Cisapride; Consciousness; Dose-Response Relationship, Drug; E | 2001 |
The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations.
Topics: Anti-Arrhythmia Agents; Astemizole; Benzimidazoles; Binding Sites; Blotting, Western; Cation Transpo | 2002 |
The T wave as a marker of dispersion of ventricular repolarization in premature infants before and while on treatment with the I(Kr) channel blocker cisapride.
Topics: Belgium; Cation Transport Proteins; Cisapride; DNA-Binding Proteins; Electrocardiography; ERG1 Potas | 2002 |
Expression and coassociation of ERG1, KCNQ1, and KCNE1 potassium channel proteins in horse heart.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Benzopyrans; Cell Line; Cisapride; Cricetinae; E | 2002 |